Anti-metastatic effects of DNA vaccine encoding single‑chain trimer composed of MHC I and vascular endothelial growth factor receptor 2 peptide

Chen,Ruiling; Wang,Shengchao; Yao,Yunliang; Zhou,Yun; Zhang,Chong; Fang,Jie; Zhang,Dayong; Zhang,Lihuang; Pan,Jianping

doi:10.3892/or.2015.3820

Anti-metastatic effects of DNA vaccine encoding single‑chain trimer composed of MHC I and vascular endothelial growth factor receptor 2 peptide

Authors:
- Ruiling Chen
- Shengchao Wang
- Yunliang Yao
- Yun Zhou
- Chong Zhang
- Jie Fang
- Dayong Zhang
- Lihuang Zhang
- Jianping Pan
View Affiliations

Affiliations: Department of Clinical Medicine, Zhejiang University City College School of Medicine, Hangzhou, Zhejiang 310015, P.R. China, Section Three of the Department of General Surgery, First Affliated Hospital, Shihezi University School of Medicine, Shihezi, Xinjiang 832008, P.R. China, Department of Microbiology and Immunology, Huzhou Teacher's College School of Medicine, Huzhou, Zhejiang 313000, P.R. China, Department of Pathogen Biology, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310058, P.R. China
Published online on: February 26, 2015 https://doi.org/10.3892/or.2015.3820
Pages: 2269-2276

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Vascular endothelial growth factor receptor 2 (VEGFR2)-mediated signaling is the key rate-limiting step in angiogenesis. VEGFR2 serves as the most important target of anti-angiogenic therapy for cancers. Single‑chain trimer (SCT) comprising antigen peptide, β2-microglobulin (β2m), and major histocompatibility complex (MHC) class I heavy chain was a particularly powerful strategy involved in the increase of the potency of DNA vaccine against tumors and infections. In the present study, we constructed an SCT-encoding VEGFR2 antigen peptide [aa400-408, also known as kinase insert domain-containing receptor (KDR2)], β2m, and mouse MHC class I heavy chain H-2Db [pcDNA3.1(+)-KDR2-β2m‑H-2Db, or SCT-KDR2]. The constructed SCT-KDR2 DNA was efficiently expressed in the human A293 embryonic kidney cell line. Intradermal immunization of C57BL/6 mice with SCT-KDR2 DNA was able to successfully break self-immunological tolerance and induce robust cytotoxic T‑lymphocyte (CTL) response to VEGFR2, leading to marked suppression of tumor cell‑induced angiogenesis and metastasis in murine models of B16 melanoma and 3LL Lewis lung carcinoma. Taken together, the results showed that VEGFR2-targeted SCT vaccination is an effective modality that can be utilized in anti-angiogenic active immunotherapy for various types of cancer.

View Figures

View References

1	Ferrara N and Kerbel RS: Angiogenesis as a therapeutic target. Nature. 438:967–974. 2005. View Article : Google Scholar : PubMed/NCBI
2	Pan J, Jin P, Yan J and Kabelitz D: Anti-angiogenic active immunotherapy: a new approach to cancer treatment. Cancer Immunol Immunother. 57:1105–1114. 2008. View Article : Google Scholar : PubMed/NCBI
3	Chung AS and Ferrara N: Developmental and pathological angiogenesis. Annu Rev Cell Dev Biol. 27:563–584. 2011. View Article : Google Scholar : PubMed/NCBI
4	Potente M, Gerhardt H and Carmeliet P: Basic and therapeutic aspects of angiogenesis. Cell. 146:873–887. 2011. View Article : Google Scholar : PubMed/NCBI
5	Yang X, Zhang XF, Lu X, Jia HL, Liang L, Dong QZ, Ye QH and Qin LX: MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway. Hepatology. 59:1874–1885. 2014. View Article : Google Scholar
6	Shojaei F: Anti-angiogenesis therapy in cancer: Current challenges and future perspectives. Cancer Lett. 320:130–137. 2012. View Article : Google Scholar : PubMed/NCBI
7	Croci DO, Cerliani JP, Dalotto-Moreno T, et al: Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell. 156:744–758. 2014. View Article : Google Scholar : PubMed/NCBI
8	Astorgues-Xerri L, Riveiro ME, Tijeras-Raballand A, Serova M, Neuzillet C, Albert S, Raymond E and Faivre S: Unraveling galectin-1 as a novel therapeutic target for cancer. Cancer Treat Rev. 40:307–319. 2014. View Article : Google Scholar
9	Cross MJ and Claesson-Welsh L: FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci. 22:201–207. 2001. View Article : Google Scholar : PubMed/NCBI
10	Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
11	Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R and Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
12	Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D and Davidson NE: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 357:2666–2676. 2007. View Article : Google Scholar : PubMed/NCBI
13	Ren S, Fengyu, Zuo S, Zhao M, Wang X, Wang X, Chen Y, Wu Z and Ren Z: Inhibition of tumor angiogenesis in lung cancer by T4 phage surface displaying mVEGFR2 vaccine. Vaccine. 29:5802–5811. 2011. View Article : Google Scholar : PubMed/NCBI
14	Bracarda S, Caserta C, Sordini L, Rossi M, Hamzay A and Crinò L: Protein kinase inhibitors in the treatment of renal cell carcinoma: Sorafenib. Ann Oncol. 18(Suppl 6): vi22–vi25. 2007. View Article : Google Scholar : PubMed/NCBI
15	Wei YQ, Wang QR, Zhao X, et al: Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med. 6:1160–1166. 2000. View Article : Google Scholar : PubMed/NCBI
16	Seavey MM, Maciag PC, Al-Rawi N, Sewell D and Paterson Y: An anti-vascular endothelial growth factor receptor 2/fetal liver kinase-1 Listeria monocytogenes anti-angiogenesis cancer vaccine for the treatment of primary and metastatic Her-2/neu⁺ breast tumors in a mouse model. J Immunol. 182:5537–5546. 2009. View Article : Google Scholar : PubMed/NCBI
17	Zuo SG, Chen Y, Wu ZP, et al: Orally administered DNA vaccine delivery by attenuated Salmonella typhimurium targeting fetal liver kinase 1 inhibits murine Lewis lung carcinoma growth and metastasis. Biol Pharm Bull. 33:174–182. 2010. View Article : Google Scholar : PubMed/NCBI
18	Li Y, Wang MN, Li H, King KD, Bassi R, Sun H, Santiago A, Hooper AT, Bohlen P and Hicklin DJ: Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J Exp Med. 195:1575–1584. 2002. View Article : Google Scholar : PubMed/NCBI
19	Nair S, Boczkowski D, Moeller B, Dewhirst M, Vieweg J and Gilboa E: Synergy between tumor immunotherapy and antiangiogenic therapy. Blood. 102:964–971. 2003. View Article : Google Scholar : PubMed/NCBI
20	Pan J, Heiser A, Marget M, Steinmann J and Kabelitz D: Enhanced antimetastatic effect of fetal liver kinase 1 extracellular domain and interferon-gamma fusion gene-modified dendritic cell vaccination. Gene Ther. 12:742–750. 2005. View Article : Google Scholar : PubMed/NCBI
21	Dong Y, Qian J, Ibrahim R, Berzofsky JA and Khleif SN: Identification of H-2Db-specific CD8+ T-cell epitopes from mouse VEGFR2 that can inhibit angiogenesis and tumor growth. J Immunother. 29:32–40. 2006. View Article : Google Scholar
22	Hansen T, Yu YY and Fremont DH: Preparation of stable single-chain trimers engineered with peptide, beta2 microglobulin, and MHC heavy chain. Curr Protoc Immunol Chapter. 17:Unit 17. 152009.
23	Huang CH, Peng S, He L, Tsai YC, Boyd DA, Hansen TH, Wu TC and Hung CF: Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope. Gene Ther. 12:1180–1186. 2005. View Article : Google Scholar : PubMed/NCBI
24	Kang TH, Mao CP, La V, Chen A, Hung CF and Wu TC: Innovative DNA vaccine to break immune tolerance against tumor self-antigen. Hum Gene Ther. 24:181–188. 2013. View Article : Google Scholar :
25	Hung CF, Calizo R, Tsai YC, He L and Wu TC: A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumors. Vaccine. 25:127–135. 2007. View Article : Google Scholar
26	Huang B, Mao CP, Peng S, He L, Hung CF and Wu TC: Intradermal administration of DNA vaccines combining a strategy to bypass antigen processing with a strategy to prolong dendritic cell survival enhances DNA vaccine potency. Vaccine. 25:7824–7831. 2007. View Article : Google Scholar : PubMed/NCBI
27	Kim S, Zuiani A, Carrero JA and Hansen TH: Single chain MHC I trimer-based DNA vaccines for protection against Listeria monocytogenes infection. Vaccine. 30:2178–2186. 2012. View Article : Google Scholar : PubMed/NCBI
28	Kim S, Li L, McMurtrey CP, Hildebrand WH, Weidanz JA, Gillanders WE, Diamond MS and Hansen TH: Single-chain HLA-A2 MHC trimers that incorporate an immundominant peptide elicit protective T cell immunity against lethal West Nile virus infection. J Immunol. 184:4423–4430. 2010. View Article : Google Scholar : PubMed/NCBI
29	Cheung YK, Cheng SC, Ke Y and Xie Y: Two novel HLA-A*0201 T-cell epitopes in avian H5N1 viral nucleoprotein induced specific immune responses in HHD mice. Vet Res. 41:242010. View Article : Google Scholar
30	Cheung YK, Cheng SC, Sin FW, Chan KT and Xie Y: Investigation of immunogenic T-cell epitopes in SARS virus nucleocapsid protein and their role in the prevention and treatment of SARS infection. Hong Kong Med J. 14(Suppl 4): 27–30. 2008.PubMed/NCBI
31	Cheung YK, Cheng SC, Sin FW, Chan KT and Xie Y: Induction of T-cell response by a DNA vaccine encoding a novel HLA-A*0201 severe acute respiratory syndrome coronavirus epitope. Vaccine. 25:6070–6077. 2007. View Article : Google Scholar : PubMed/NCBI
32	Hu YX, Li M, Jia XH, Du QX, Miao FT, Yao L and Shen JD: HPV16 CTL epitope peptide-activated dendritic cell and natural killer co-culture for therapy of cervical cancer in an animal model. Asian Pac J Cancer Prev. 14:7335–7338. 2013. View Article : Google Scholar
33	Wang D, Stockard CR, Harkins L, et al: Immunohistochemistry in the evaluation of neovascularization in tumor xenografts. Biotech Histochem. 83:179–189. 2008. View Article : Google Scholar : PubMed/NCBI
34	Ellis LM and Hicklin DJ: VEGF-targeted therapy: Mechanisms of anti-tumour activity. Nat Rev Cancer. 8:579–591. 2008. View Article : Google Scholar : PubMed/NCBI
35	Ebos JM, Lee CR and Kerbel RS: Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res. 15:5020–5025. 2009. View Article : Google Scholar : PubMed/NCBI
36	Yu YY, Netuschil N, Lybarger L, Connolly JM and Hansen TH: Cutting edge: Single-chain trimers of MHC class I molecules form stable structures that potently stimulate antigen-specific T cells and B cells. J Immunol. 168:3145–3149. 2002. View Article : Google Scholar : PubMed/NCBI
37	Lybarger L, Yu YY, Miley MJ, Fremont DH, Myers N, Primeau T, Truscott SM, Connolly JM and Hansen TH: Enhanced immune presentation of a single-chain major histocompatibility complex class I molecule engineered to optimize linkage of a C-terminally extended peptide. J Biol Chem. 278:27105–27111. 2003. View Article : Google Scholar : PubMed/NCBI
38	Kanagawa N, Yanagawa T, Nakagawa T, Okada N and Nakagawa S: Tumor vessel-injuring ability improves antitumor effect of cytotoxic T lymphocytes in adoptive immunotherapy. Cancer Gene Ther. 20:57–64. 2013. View Article : Google Scholar :